Table 4 Acute toxicity of the IGEFA administered orally to different groups of mice
Treatment | Dose (mg/kg) | Sex | D/T | Mortality latency (h) | Toxic symptoms |
|---|---|---|---|---|---|
Vehicle | – | Male | 0/5 | – | None |
Female | 0/5 | – | None | ||
IGEFA | 5 | Male | 0/5 | – | None |
Female | 0/5 | – | None | ||
IGEFA | 15 | Male | 0/5 | – | None |
Female | 0/5 | – | None | ||
IGEFA | 30 | Male | 0/5 | – | None |
Female | 0/5 | – | None | ||
IGEFA | 90 | Male | 0/5 | – | None |
Female | 0/5 | – | None | ||
IGEFA | 180 | Male | 0/5 | – | None |
Female | 0/5 | – | None | ||
IGEFA | 360 | Male | 0/5 | – | None |
Female | 0/5 | – | None | ||
IGEFA | 720 | Male | 3/5 | 36–48 | Hypoactivity, piloerection, salivation |
Female | 5/5 | 36–48 | Hypoactivity, piloerection, salivation | ||
IGEFA | 1440 | Male | 4/5 | 24–36 | Hypoactivity, piloerection, salivation |
Female | 5/5 | 24–36 | Hypoactivity, piloerection, salivation | ||
IGEFA | 2880 | Male | 5/5 | 24–36 | Hypoactivity, piloerection, salivation |
Female | 5/5 | 36–48 | Hypoactivity, piloerection, salivation | ||
IGEFA | 5760 | Male | 5/5 | 36–48 | Asthenia, anorexia, salivation, asthenia |
Female | 5/5 | 36–48 | Asthenia, anorexia, salivation, asthenia |